Actively Recruiting
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Led by Biohaven Therapeutics Ltd. · Updated on 2026-06-02
20
Participants Needed
15
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating BHV-1400 as a treatment for adults with IgA Nephropathy (IgAN), a kidney condition confirmed by biopsy. This Phase 1 study aims to assess the safety and tolerability of BHV-1400 in people diagnosed with this disease. The study is sponsored by Biohaven Therapeutics Ltd. and involves participants aged 18 to 65 years. Participants will receive BHV-1400, which is given as a subcutaneous injection under the skin. This is an open-label study, meaning both researchers and participants know the treatment being given. The focus is on monitoring for any serious adverse events, side effects leading to stopping the treatment, deaths, and significant laboratory changes during up to one year of follow-up. During the study, participants will be closely monitored for safety through regular assessments and laboratory tests. The main outcomes measured include the number of participants who experience serious side effects or severe lab abnormalities within one year. Participants can expect ongoing evaluations to track their health status while receiving the study treatment. The study is planned to run until July 2027.
CONDITIONS
Brief Title
Study of BHV-1400 in IgA Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have biopsy-confirmed IgA Nephropathy
- Participants must be between 18 and 65 years old
You will not qualify if you...
- Any secondary IgA Nephropathy
- Any chronic kidney disease not caused by IgA Nephropathy or due to non-IgAN causes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants receive BHV-1400 delivered subcutaneously as part of their treatment.
Trial Site Locations
Total: 15 locations
1
Site-001
Farmington, Connecticut, United States, 06030
Actively Recruiting
2
Site-003
Miami Lakes, Florida, United States, 33016
Actively Recruiting
3
Site-011
Miami Lakes, Florida, United States, 33172
Actively Recruiting
4
Site-013
Orlando, Florida, United States, 32806
Actively Recruiting
5
Site-005
Pembroke Pines, Florida, United States, 33029
Actively Recruiting
6
Site-008
Lawrenceville, Georgia, United States, 30046
Actively Recruiting
7
Site-009
Hinsdale, Illinois, United States, 60521
Actively Recruiting
8
Site-012
Indianapolis, Indiana, United States, 46268
Actively Recruiting
9
Site-015
Shelby, Michigan, United States, 48316
Not Yet Recruiting
10
Site-006
Chesterfield, Missouri, United States, 63017
Actively Recruiting
11
Site-002
Dakota Dunes, South Dakota, United States, 57049
Actively Recruiting
12
Site-014
Houston, Texas, United States, 77027
Actively Recruiting
13
Site-004
Houston, Texas, United States, 77099
Actively Recruiting
14
Site-016
Salt Lake City, Utah, United States, 84115
Actively Recruiting
15
Site-007
Leicester, United Kingdom, LE5 4PW
Actively Recruiting
Research Team
C
Chief Medical Officer
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here